Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Adrian Săftoiu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-7993-8269; OpenAlex author ID A5035898359. Sources: OpenAlex.

Their work

Papers
21 (first author 1, last author 11)
Trials
0
Grants
0
Labs led
2
Collaborators
43
Papers, trials and grants by year

2013: 2 papers · 2014: none · 2015: 1 paper · 2016: 1 paper · 2017: 3 papers · 2018: 1 paper · 2019: 3 papers · 2020: 3 papers · 2021: 1 paper · 2022: 2 papers · 2023: none · 2024: 1 paper · 2025: 3 papers

Papers 21

  1. Fatty pancreas on EUS: Risk factors, correlation with CT/MRI, and implications for pancreatic cancer screening. Co-author DOI 10.1097/eus.0000000000000109↗
  2. Clinicopathologic relevance of EpCAM and CD44 in pancreatic cancer: insights from a meta-analysis. Last author DOI 10.1186/s13287-025-04601-1↗
  3. Endoscopic Ultrasound-Guided Radiofrequency Ablation for Pancreatic Adenocarcinoma: A Scoping Review with Meta-Analysis. Last author DOI 10.3390/diagnostics15040437↗
  4. Deep learning segmentation architectures for automatic detection of pancreatic ductal adenocarcinoma in EUS-guided fine-needle biopsy samples based on whole-sl… Last author DOI 10.1097/eus.0000000000000094↗
  5. Quantitative contrast-enhanced endoscopic ultrasound in pancreatic ductal adenocarcinoma and pancreatic neuroendocrine tumors: can we predict survival using pe… Last author DOI 10.11152/mu-3503↗
  6. Evaluation of MMR Status and PD-L1 Expression Using Specimens Obtained by EUS-FNB in Patients with Pancreatic Ductal Adenocarcinoma (PDAC). Last author DOI 10.3390/diagnostics12020294↗
  7. Prognostic biomarkers related to tumoral microenvironment in pancreatic ductal adenocarcinoma: a systematic review. Last author DOI 10.47162/rjme.62.3.03↗
  8. Endoscopic Ultrasound-Guided Treatment of Pancreatic Cancer. Co-author DOI 10.1007/s11894-020-00767-1↗
  9. Morphometric Assessment of Confocal Laser Endomicroscopy for Pancreatic Ductal Adenocarcinoma, an Ex-Vivo Pilot Study. Last author DOI 10.3390/diagnostics10110923↗
  10. Quality of life impact of EUS in patients at risk for developing pancreatic cancer. Co-author DOI 10.4103/eus.eus_56_19↗
  11. Changes in tumor vascularity depicted by contrast-enhanced EUS as a predictor of prognosis and treatment efficacy in patients with unresectable pancreatic canc… First author DOI 10.4103/eus.eus_16_19↗
  12. Psychological impact of pancreatic cancer screening by EUS or magnetic resonance imaging in high-risk individuals: A systematic review. Last author DOI 10.4103/eus.eus_25_18↗
  13. Artificial intelligence in pancreatic cancer: Toward precision diagnosis. Co-author DOI 10.4103/eus.eus_76_19↗
  14. A Diagnostic Challenge: Pancreatic Cancer or Autoimmune Pancreatitis? Co-author DOI 10.12865/chsj.44.02.15↗
  15. Which is the Best Imaging Method in Pancreatic Adenocarcinoma Diagnosis and Staging - CT, MRI or EUS? Co-author DOI 10.12865/chsj.43.02.05↗
  16. Molecular Analysis of Vascular Endothelial Growth Factor (VEGF) Receptors in EUS-guided Samples Obtained from Patients with Pancreatic Adenocarcinoma. Last author DOI 10.15403/jgld.2014.1121.261.eus↗
  17. The borderline resectable/locally advanced pancreatic ductal adenocarcinoma: EUS oriented. Co-author DOI 10.4103/eus.eus_68_17↗
  18. The role of contrast-enhanced endoscopic ultrasound in pancreatic adenocarcinoma. Co-author DOI 10.4103/2303-9027.190932↗
  19. VEGF Expression in Pancreatic Cancer and Other Malignancies: A Review of the Literature. Last author DOI 10.1515/rjim-2015-0027↗
  20. Quantitative low mechanical index contrast-enhanced endoscopic ultrasound for the differential diagnosis of chronic pseudotumoral pancreatitis and pancreatic c… Last author DOI 10.1186/1471-230x-13-2↗
  21. Feasibility study of EUS-NOTES as a novel approach for pancreatic cancer staging and therapy: an international collaborative study. Co-author DOI 10.5754/hge11774↗

Closest collaborators

The 25 strongest of 43 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Irina Mihaela Cazacu · 9 shared papers, 2019–2025 · strength 1.29
  2. Manoop S. Bhutani · 9 shared papers, 2013–2025 · strength 1.07
  3. Bogdan Silviu Ungureanu · 4 shared papers, 2020–2025 · strength 0.77
  4. Alina Liliana Constantin · 5 shared papers, 2019–2024 · strength 0.75
  5. Daniela Tabacelia · 2 shared papers, 2022–2025 · strength 0.41
  6. Matthew H. G. Katz · 3 shared papers, 2013–2025 · strength 0.36
  7. Mariana Jinga · 2 shared papers, 2019–2025 · strength 0.34
  8. Stephen P. Pereira · 2 shared papers, 2019–2025 · strength 0.34
  9. Florencia M. McAllister · 2 shared papers, 2020–2025 · strength 0.33
  10. Ștefan Udriștoiu · 2 shared papers, 2019–2024 · strength 0.32
  11. Dan Ionuț Gheonea · 2 shared papers, 2013–2025 · strength 0.32
  12. Cristian George Ţieranu · 1 shared paper, 2025 · strength 0.27
  13. Daniel Vasile Balaban · 1 shared paper, 2025 · strength 0.27
  14. Cristian Gheorghe · 1 shared paper, 2025 · strength 0.27
  15. Ramez M. Ibrahim · 1 shared paper, 2025 · strength 0.24
  16. Michael P. Kim · 1 shared paper, 2025 · strength 0.24
  17. Mădălin Ionuţ Costache · 3 shared papers, 2015–2017 · strength 0.21
  18. Peter Vilmann · 3 shared papers, 2013–2019 · strength 0.20
  19. Valeriu Şurlin · 2 shared papers, 2013–2020 · strength 0.16
  20. Simona Dima · 1 shared paper, 2020 · strength 0.13
  21. Irinel Popescu · 1 shared paper, 2020 · strength 0.13
  22. Dana-Maria Albulescu · 1 shared paper, 2017 · strength 0.12
  23. Gabriel Gruionu · 1 shared paper, 2019 · strength 0.11
  24. IM Cazacu · 1 shared paper, 2018 · strength 0.10
  25. Priya Bhosale · 1 shared paper, 2018 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.